A phase I trial of IBIO-CFB03 for treatment of fibrotic diseases

Trial Profile

A phase I trial of IBIO-CFB03 for treatment of fibrotic diseases

Planning
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs IBIO CFB03 (Primary)
  • Indications Pulmonary fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jul 2016 According to an iBio Inc media release, the company has announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to iBio-CFB03, for the treatment of systemic sclerosis.
    • 23 Sep 2015 New trial record
    • 09 Sep 2015 According to an iBio Inc media release, this trial has been funded by a grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under its Small Business Technology Transfer (STTR) program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top